Sugi Predict

Sugi Predict / Compounds / SCHEMBL1506792

SCHEMBL1506792

SCHEMBL1506792

CCCCCCCC/C=C\CCCCCCCCOCC(COC(C)=O)OC(C)=O

nearest known ligand 0.62

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ PRKCA P17252 3/20 0.61
▸ LPAR1 Q92633 2/20 0.50
▸ LPAR3 Q9UBY5 2/20 0.50
▸ PRKCE Q02156 1/20 0.50
▸ PRKCQ Q04759 1/20 0.50
▸ PRKCD Q05655 1/20 0.50
▸ ADRA1D P25100 1/20 0.49
▸ PTAFR P25105 1/20 0.49
▸ HTR1D P28221 1/20 0.49
▸ HTR2C P28335 1/20 0.49
▸ ADRA1B P35368 1/20 0.49
▸ DRD3 P35462 1/20 0.49
▸ TMEM97 Q5BJF2 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1506794 1.00 PRKCA (0.61) PRKCALPAR1LPAR3PRKCEPRKCQ
SCHEMBL6798446 0.94 LPAR1 (0.55) PRKCALPAR1LPAR3ADRA1DPTAFR
SCHEMBL6798442 0.94 LPAR1 (0.55) PRKCALPAR1LPAR3ADRA1DPTAFR
SCHEMBL8435468 0.91 ADRA1D (0.55) PRKCAADRA1DPTAFRHTR1DHTR2C
SCHEMBL10894210 0.91 ADRA1D (0.55) PRKCAADRA1DPTAFRHTR1DHTR2C
SCHEMBL10824976 0.91 ADRA1D (0.55) PRKCAADRA1DPTAFRHTR1DHTR2C
SCHEMBL8438758 0.91 ADRA1D (0.55) PRKCAADRA1DPTAFRHTR1DHTR2C
SCHEMBL30385293 0.89 PRKCA (0.57) PRKCALPAR1LPAR3PRKCEPRKCQ
Triacetin SCHEMBL17821531 0.88 PRKCA (0.55) PRKCAADRA1DPTAFRHTR1DHTR2C
SCHEMBL4912512 0.87 PRKCA (0.62) PRKCALPAR1LPAR3PRKCEPRKCQ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0101046-B1 METHODS, COMPOSITIONS AND ELEMENTS FOR THE DETERMINATION OF LIPASE EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1986-08-06 — — EP claimed
US-4555483-A GLYCEROL TRIESTER SUBSTRATE; ESTERASE ENZYME; DETECTING RATE OF FORMATION OF GLYCEROL EASTMAN KODAK COMPANY (US) 1985-11-26 — — US claimed
EP-0101046-A1 Methods, compositions and elements for the determination of lipase EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1984-02-22 — — EP claimed
US-9089484-B2 Pharmaceutical compositions of selective factor Xa inhibitors for oral administration MERRION RESEARCH III LIMITED (IE) 2015-07-28 — — US disclosed
US-8753683-B2 Delivery of a bioactive material MERRION RESEARCH III LIMITED (IE) 2014-06-17 — — US disclosed
EP-2651395-A1 PHARMACEUTICAL COMPOSITIONS OF SELECTIVE FACTOR XA INHIBITORS FOR ORAL ADMINISTRATION Merrion Research III Limited (IE) 2013-10-23 — — EP disclosed
US-20120156294-A1 Pharmaceutical Compositions of Selective Factor Xa Inhibitors for Oral Administration NOVO NORDISK A/S (DK) 2012-06-21 — — US disclosed
WO-2012082209-A1 PHARMACEUTICAL COMPOSITIONS OF SELECTIVE FACTOR XA INHIBITORS FOR ORAL ADMINISTRATION MERRION RESEARCH III LIMITED (IE) 2012-06-21 — — WO disclosed
WO-2011120033-A1 PHARMACEUTICAL COMPOSITIONS OF SELECTIVE FACTOR XA INHIBITORS FOR ORAL ADMINISTRATION MERRION RESEARCH III LIMITED (IE) 2011-09-29 — — WO disclosed
US-20110236474-A1 Pharmaceutical Compositions of Selective Factor Xa Inhibitors for Oral Administration NOVO NORDISK A/S (DK) 2011-09-29 — — US disclosed
EP-2292225-A1 Dosage form comprising taxol in crystalline form BOSTON SCIENTIFIC SCIMED LIMITED (BB) 2011-03-09 — — EP disclosed
EP-0580778-A4 CONVERTIBLE MICROEMULSION FORMULATIONS AFFINITY BIOTECH INC (US) 1996-01-31 — — EP disclosed
US-5444041-A Water-in-oil which readily converts to an oil-in-water emulsion by addition of aqueous fluid; used as sustained release agent for water soluble biologically active materials IBAH, INC. (US) 1995-08-22 — — US disclosed
WO-1995014037-A1 TRANSPARENT LIQUID FOR ENCAPSULATED DRUG DELIVERY IBAH, INC. (US) 1995-05-26 — — WO disclosed
WO-1994008604-A1 CONVERTIBLE MICROEMULSION FORMULATIONS AFFINITY BIOTECH, INC. (US) 1994-04-28 — — WO disclosed
EP-0580778-A1 CONVERTIBLE MICROEMULSION FORMULATIONS IBAH, Inc. (US) 1994-02-02 — — EP disclosed
WO-1992018147-A1 CONVERTIBLE MICROEMULSION FORMULATIONS AFFINITY BIOTECH, INC. (US) 1992-10-29 — — WO disclosed
EP-0101046-B1 METHODS, COMPOSITIONS AND ELEMENTS FOR THE DETERMINATION OF LIPASE EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1986-08-06 — — EP disclosed
US-4555483-A GLYCEROL TRIESTER SUBSTRATE; ESTERASE ENZYME; DETECTING RATE OF FORMATION OF GLYCEROL EASTMAN KODAK COMPANY (US) 1985-11-26 — — US disclosed
EP-0101046-A1 Methods, compositions and elements for the determination of lipase EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1984-02-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110236474-A1 Pharmaceutical Compositions of Selective Factor Xa Inhibitors for Oral Administration F12, F13B, F11 PRKCA 3450/4885LPAR1 276/4885LPAR3 249/4885
US-20120156294-A1 Pharmaceutical Compositions of Selective Factor Xa Inhibitors for Oral Administration F12, F13B, F11 PRKCA 3546/4885LPAR1 365/4885LPAR3 317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.